Format

Send to

Choose Destination
Nat Rev Drug Discov. 2014 Dec;13(12):904-27. doi: 10.1038/nrd4390. Epub 2014 Nov 7.

Is there new hope for therapeutic matrix metalloproteinase inhibition?

Author information

1
1] Inflammation Research Center - VIB, Rijvisschestraat 120 9052 Ghent, Belgium. [2] Department of Biomedical Molecular Biology - Ghent University, FSVM Building, Technologiepark 927, B-9052 Zwijnaarde, Ghent, Belgium.

Abstract

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that form a family of 24 members in mammals. Evidence of the pathological roles of MMPs in various diseases, combined with their druggability, has made them attractive therapeutic targets. Initial drug discovery efforts focused on the roles of MMPs in cancer progression, and more than 50 MMP inhibitors have been investigated in clinical trials in various cancers. However, all of these trials failed. Reasons for failure include the lack of inhibitor specificity and insufficient knowledge about the complexity of the disease biology. MMPs are also known to be involved in several inflammatory processes, and there are new therapeutic opportunities for MMP inhibitors to treat such diseases. In this Review, we discuss the recent advances made in understanding the role of MMPs in inflammatory diseases and the therapeutic potential of MMP inhibition in those conditions.

PMID:
25376097
DOI:
10.1038/nrd4390
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center